TENKASI 400 mg, powder for concentrate for infusion 3 bottles of 50 ml
Active ingredients: Oritavancin diphosphate, Oritavancin
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for concentrate for infusion3 bottles of 50 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TENKASI 400 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 3 flacons en verre de 50 mL
- Marketing authorisation holder
- MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 May 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67623773CIP75500872CIP133400955008729Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DIPHOSPHATE D'ORITAVANCINEpoudre | 443,7 mg · un flacon | SA |
| ORITAVANCINEpoudre | 400 mg · un flacon | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.